New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
09:47 EDTTEVA, PG, ACTTeva announces new organizational structure, senior leadership changes
Teva Pharmaceutical Industries announced a new organizational structure and related executive positions, which will become effective July 1. These changes are another key step in Teva's strategic direction to create a less complex, integrated company that can address the evolving needs of patients in the global markets in the most efficient, innovative and differentiated manner possible, the company said. Teva will be spearheaded by two commercial business units Global Specialty Medicines, established in April 2013, and the newly-formed Global Generic Medicines group. GGM will have full global responsibility for all existing generic markets. GGM will also be responsible for Teva's growing Over-the-Counter (OTC) business, led by Teva's joint venture with Procter and Gamble (PG). Teva announced that Sigurdur Olafsson has been appointed President and CEO of the newly formed Global Generic Medicines group and will assume this position on July 1, based in the U.S. Olafsson joins Teva from his previous role as President of Actavis Pharma (ACT). GSM, led by Dr. Rob Koremans, is responsible for Teva's global specialty medicines business and will continue to drive organic growth, with a strong pipeline of patient-centric solutions and new brands.
News For TEVA;PG;ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 24, 2014
08:59 EDTPGProcter & Gamble expects headwinds facing industry to continue
Subscribe for More Information
07:07 EDTPGProcter & Gamble reports Q1 organic volume unchanged from prior year
Subscribe for More Information
07:05 EDTPGProcter & Gamble reiterates FY15 organic sales growth, core EPS growth view
P&G reiterated its organic sales growth and core earnings per share growth guidance ranges for FY15. P&G added that the quarterly profile of earnings will be heavily influenced by the variation of foreign exchange impacts from period-to-period. The company expects significant negative sales and earnings impacts from foreign exchange in the October-December 2014 quarter. The company continues to expect organic sales growth in the low-to-mid single digit range. Net sales growth is now expected to be in-line to up low single digits versus the prior fiscal year, including a negative two point impact from foreign exchange. P&G maintained its outlook for core earnings per share growth in the range of mid-single digits. All-in GAAP diluted net earnings per share are now expected to be down two percent to down five percent versus the prior year, including approximately 55c per share of non-core charges, primarily from 20c per share of non-core restructuring charges and 32c of impairment charges.
07:04 EDTPGProcter & Gamble announces plans for Duracell exit
Subscribe for More Information
07:02 EDTPGProcter & Gamble reports Q1 core EPS $1.07, consensus $1.07
Subscribe for More Information
October 23, 2014
18:18 EDTACTGlenview Capital acquires stake in Actavis, Bloomberg reports
Subscribe for More Information
15:44 EDTPGProcter & Gamble October weekly 83 straddle priced for 2% move into Q1
Subscribe for More Information
15:39 EDTPGNotable companies reporting before tomorrow's open
Subscribe for More Information
08:10 EDTACTActavis confirms appeals court upholds Lo Loestrin Fe patent
Subscribe for More Information
06:25 EDTPGLuxottica announces arrival of co-CEO for Markets Adil Mehboob-Khan
Subscribe for More Information
06:13 EDTPGProcter & Gamble narrows potential CEO successors to four, WSJ reports
Subscribe for More Information
October 22, 2014
18:14 EDTPGProcter & Gamble narrows pool of potential CEO candidates, WSJ says
Subscribe for More Information
14:20 EDTPGProcter & Gamble October weekly volatility increases into Q1 and outlook
Subscribe for More Information
12:09 EDTPGLuxottica to name P&G executive as co-CEO, Bloomberg says
Eyeglass maker Luxottica (LUX), which is in the midst of a boardroom upheaval, will name Procter & Gamble (PG) executive Adil Mehboob-Khan as a co-CEO, says Bloomberg, citing people familiar with the matter. Reference Link
08:38 EDTACTActavis signs option to acquire Rhythm Health
Subscribe for More Information
October 21, 2014
06:44 EDTACTActavis among bidders for Omega Pharma, Bloomberg reports
Subscribe for More Information
October 20, 2014
18:51 EDTACTOn The Fly: After Hours Movers
Subscribe for More Information
06:28 EDTACT, TEVAAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
October 17, 2014
09:47 EDTACTValeant will not raise Allergan bid ahead of record date, CNBC reports
Valeant (VRX) will not raise its hostile takeover bid for Allergan (AGN) ahead of the record date for the vote, CNBC's David Faber reports. Allergan (AGN) is not currently in takeover talks with Actavis (ACT), Faber added.
09:45 EDTACTAllergan not in deal talks with Actavis, CNBC reports
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use